UCB S.A. UCB

UCB (UCBJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

UCB SA (UCBJF) reports 23% net sales growth to EUR4.1 billion, with BIMZELX doubling to EUR1.5 billion and upgraded full-year guidance reflecting robust operating leverage.

Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposureReduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observe

Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus placebo plus standard of careFindings showed results in favor of dapirolizumab pegol plus standard of care versus placebo plus standard of care across endpoints, including multiple disease activity measures, severe flares, patient-reported outcomes, including fatigue, and glucocort

Investors may be wondering if UCB's share price still reflects good value after a strong run, or if most of the opportunity is already priced in. UCB's share price closed at €246.30, with a 1 year return of 68.3% and a 3 year return of 195.3%. The 7 day and 30 day returns of a 4.8% decline and a 0.4% decline suggest some recent cooling after a longer period of strength. Recent headlines around UCB have focused on its position in the pharmaceuticals and biotech space, as investors reassess...

Conference data puts UCB’s neurology pipeline in focus UCB (ENXTBR:UCB) is in the spotlight after presenting 21 neurology abstracts at the American Academy of Neurology 2026 meeting, including new real world data on developmental and epileptic encephalopathies and generalized myasthenia gravis. See our latest analysis for UCB. Despite a 1-day share price return of 1.32% to €246.3 after the neurology data updates, UCB’s recent 7-day and 90-day share price returns of 4.79% and 4.31% declines...

UCB (UCBJY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

UCB S.A. has key market opportunities in developing biopharmaceuticals addressing autoimmune and neurological diseases. Their focus on digital transformation, innovation, and tech partnerships aims to advance product launches and strategic initiatives in these therapeutic areas.Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: UCB - 2025" company profile has been added to ResearchAndMarkets.com's offering. The report provides insights into the company's tech activ

CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders to the general meeting of the shareholders (the “General Meeting”) which will be held on Thursday, 30 April 2026, at 11:00 am CEST, at the registered office of UCB SA/NV, Allée de la Recherche 60 - 1070 Brussels, for the purpose of considering and voting on the items shown on the agenda set out below. Applicable participation formalities are detailed at the end of this convening notice. Shareh

UCB SA (UCBJF) reports robust financial performance with significant sales growth and strategic initiatives, despite facing market challenges.

UCB (ENXTBR:UCB) shares have caught more attention lately thanks to a mix of solid recent performance and strong momentum over the past month. Investors are watching closely to see if this trend continues. See our latest analysis for UCB. UCB’s share price has been quietly building momentum, with a solid 1-year total shareholder return of 0.5% reflecting investor confidence in the company's fundamentals and future prospects. Recent movements suggest the market is warming up to UCB's growth...